Medical Devices

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

New Medicare billing codes for the biosimilar Tyenne are now in effect, simplifying reimbursement and aiming to improve access for severe COVID-19 patients.

A Sarasota innovator challenges orthopedic giants with a resorbable device that works with the body, promising faster, better patient recovery.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

OncoC4 begins a landmark trial for ONC-841, a drug targeting immune cells in the brain, offering a new front in the fight against Alzheimer's disease.

AllRock Bio has begun a Phase 2a trial for its novel drug ROC-101, testing it in combination with new standard-of-care therapies for pulmonary hypertension.

A Swiss biotech's novel antibiotic has entered human trials with new funding, offering a fresh hope against the world's most dangerous superbugs.

A new paper warns that Lyme disease may pass from mother to child, a risk overlooked for decades. Researchers are now demanding urgent action and funding.

Aptar Digital Health and Enable Injections are pairing the enFuse® wearable injector with a new digital app to transform self-care for chronic diseases.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

As Spectral AI preps its revolutionary DeepView wound scanner for launch, new CFO David McGuire brings crucial public company expertise to a pivotal transition.

Ovid Therapeutics is spotlighting a novel drug class targeting KCC2, a key brain protein. Could this be the key to treating psychosis and epilepsy?

CorTec's brain-computer interface gets FDA Breakthrough status, offering new hope for restoring movement in millions of chronic stroke survivors.

Acclaro Medical's new AuraLux laser combines 'cold ablative' tech with a unique business partnership, aiming to make advanced skin treatments safe for all.

Debuting at SIR 2026, DeepSight's NeedleVue Mini aims to democratize advanced procedural guidance by upgrading existing ultrasound systems everywhere.

The eyecare tech leader will demo its redesigned EHR at ASCRS 2026, promising streamlined workflows. But can it stand out in a competitive market?

KingstronBio's successful implant of its advanced ProStyle M® heart valve kicks off a key study, signaling a new era for patients and China's medtech.